| Year |
Citation |
Score |
| 2024 |
Tran S, Sipila P, Thakur S, Zhang C, Narendran A. Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10. Cancers. 16. PMID 38672602 DOI: 10.3390/cancers16081520 |
0.348 |
|
| 2024 |
Sarkar S, Chanda A, Khanolkar RA, Lambie M, Ailles L, Bratman SV, Narendran A, Bose P. Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy. Biomedicines. 12. PMID 38540116 DOI: 10.3390/biomedicines12030503 |
0.358 |
|
| 2023 |
Sharma R, Zhang C, Narendran A. The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia. Genes. 14. PMID 37895265 DOI: 10.3390/genes14101916 |
0.421 |
|
| 2023 |
Sharma R, Incoronato A, Zhang C, Jayanthan A, Shah R, Narendran A. Establishment of a t(11;19), KMT2A Rearranged B-ALL Cell Line for Preclinical Evaluation and Novel Therapeutics Development for Refractory Infant Leukemia. Journal of Pediatric Hematology/Oncology. 45: e750-e756. PMID 37494611 DOI: 10.1097/MPH.0000000000002697 |
0.734 |
|
| 2022 |
Grundy M, Narendran A. The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents. Frontiers in Pediatrics. 10: 910268. PMID 36034555 DOI: 10.3389/fped.2022.910268 |
0.365 |
|
| 2021 |
Banderali U, Jain M, Thakur S, Jayanthan A, Belke DD, Giles WR, Narendran A. The T-type Calcium Channel Cav3.1 in Y79 Retinoblastoma Cells is Regulated by the Epidermal Growth Factor Receptor via the MAPK Signaling Pathway. Current Eye Research. 1-10. PMID 34674590 DOI: 10.1080/02713683.2021.1988982 |
0.661 |
|
| 2021 |
Al-Ghabkari A, Narendran A. Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells . Cancer Biology & Therapy. 22: 333-344. PMID 33978549 DOI: 10.1080/15384047.2021.1902913 |
0.399 |
|
| 2021 |
Thakur S, Ruan Y, Jayanthan A, Boklan J, Narendran A. Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib. Current Cancer Drug Targets. PMID 33949932 DOI: 10.2174/1568009621666210504085527 |
0.708 |
|
| 2020 |
Thakur S, Ruan Y, Zhang C, Lun X, Jayanthan A, Narendran A. Human SNF5 arming of double-deleted vaccinia virus shows oncolytic and cytostatic activity against central nervous system atypical teratoid/rhabdoid tumor cells. Cancer Gene Therapy. PMID 32678303 DOI: 10.1038/S41417-020-0199-2 |
0.717 |
|
| 2019 |
Obaid H, Kannappan S, Gupta M, Ruan Y, Zhang C, Bose P, Narendran A. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors. Current Cancer Drug Targets. PMID 31713485 DOI: 10.2174/1568009619666191111153049 |
0.432 |
|
| 2019 |
Brennan L, Narendran A. Cancer Stem Cells in the Development of Novel Therapeutics for Refractory Pediatric Leukemia. Stem Cells and Development. PMID 31364487 DOI: 10.1089/Scd.2019.0035 |
0.442 |
|
| 2019 |
Swift L, Zhang C, Kovalchuk O, Boklan J, Trippett T, Narendran A. Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma. Investigational New Drugs. PMID 31264069 DOI: 10.1007/S10637-019-00816-1 |
0.462 |
|
| 2019 |
Al-Ghabkari A, Qasrawi DO, Alshehri M, Narendran A. Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration. Journal of Cancer Research and Clinical Oncology. PMID 31006845 DOI: 10.1007/S00432-019-02913-3 |
0.347 |
|
| 2019 |
Al-Ghabkari A, Perinpanayagam MA, Narendran A. Inhibition of PI3K/mTOR pathways with GDC-0980 in pediatric leukemia: Impact on abnormal FLT-3 activity and cooperation with intracellular signaling targets. Current Cancer Drug Targets. PMID 30914027 DOI: 10.2174/1568009619666190326120833 |
0.376 |
|
| 2019 |
Swift L, Zhang C, Trippett T, Narendran A. Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma. Oncotargets and Therapy. 12: 1293-1307. PMID 30863096 DOI: 10.2147/Ott.S191478 |
0.385 |
|
| 2019 |
Al-Ghabkari A, Narendran A. In Vitro Characterization of a Potent p53-MDM2 Inhibitor, RG7112 in Neuroblastoma Cancer Cell Lines. Cancer Biotherapy & Radiopharmaceuticals. PMID 30724592 DOI: 10.1089/Cbr.2018.2732 |
0.396 |
|
| 2019 |
Jayanthan A, Hofmann B, Meier-Stephenson V, Perinpanayagam M, Dunn SE, Boklan J, Trippett TM, Truong TH, Narendran A. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells. Journal of Pediatric Hematology/Oncology. PMID 30702467 DOI: 10.1097/Mph.0000000000001416 |
0.716 |
|
| 2019 |
Swift L, Zhang C, Pfaffle A, Chew P, Kovalchuk O, Trippett TM, Narendran A. Effective targeted antitumor activity of the antimicrobial agent taurolidine against relapsed/refractory neuroblastoma: Cytotoxicity, target modulation and tumor xenograft studies. Journal of Clinical Oncology. 37: e21502-e21502. DOI: 10.1200/Jco.2019.37.15_Suppl.E21502 |
0.509 |
|
| 2019 |
Tran S, Gupta M, Kannappan S, Zhang C, Narendran A. Targeting Neurotrophic Receptor Tyrosine Kinase (NTRK) Fusion Structural Homologs in Refractory Pediatric Acute Lymphoblastic Leukemia (ALL) Blood. 134: 3882-3882. DOI: 10.1182/Blood-2019-132223 |
0.347 |
|
| 2019 |
Zhang C, Sharma R, Satbir T, Cheney A, Vaske O, Sanders L, Boklan J, Lewis VA, Anderson R, Kovalchuk O, Lacayo NJ, Narendran A, Bielamowicz KJ. Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia Blood. 134: 2633-2633. DOI: 10.1182/Blood-2019-131444 |
0.523 |
|
| 2019 |
Kannappan S, Gupta M, Zhang C, Hofmann B, Chi S, Hanson D, Narendran A. ATRT-15. TARGETING LIN28 REGULATED PATHWAYS IN NOVEL THERAPEUTICS DEVELOPMENT FOR CNS ATYPICAL TERATOID/RHABDOID TUMOR (CNS ATRT) Neuro-Oncology. 21: ii66-ii66. DOI: 10.1093/Neuonc/Noz036.013 |
0.393 |
|
| 2018 |
Swift L, Jayanthan A, Ruan Y, Anderson R, Boklan J, Trippett T, Narendran A. Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib. Targeted Oncology. PMID 30446871 DOI: 10.1007/S11523-018-0603-0 |
0.738 |
|
| 2018 |
Bertram KL, Narendran N, Tailor P, Jablonski C, Leonard C, Irvine E, Hess R, Masson AO, Abubacker S, Rinker K, Biernaskie J, Yates RM, Salo P, Narendran A, Krawetz RJ. 17-DMAG regulates p21 expression to induce chondrogenesis and . Disease Models & Mechanisms. 11. PMID 30305302 DOI: 10.1242/Dmm.033662 |
0.3 |
|
| 2018 |
Swift L, Zhang C, Trippett TM, Narendran A. In vitro and xenograft anti-tumor activity, target modulation and drug synergy studies of PV-10 against refractory pediatric solid tumors. Journal of Clinical Oncology. 36: 10557-10557. DOI: 10.1200/Jco.2018.36.15_Suppl.10557 |
0.418 |
|
| 2018 |
Swift L, Zhang C, Shah R, Trippett T, Narendran A. In Vitro Activity and Target Modulation of PV-10 Against Relapsed and Refractory Pediatric Leukemia Blood. 132: 5207-5207. DOI: 10.1182/Blood-2018-99-119438 |
0.515 |
|
| 2018 |
Hofmann B, Kannappan S, Mehul G, Zhang C, Chi S, Hanson D, Anderson R, Narendran A. Targeting Oncogenic Polyamines in Refractory Pediatric Leukemias Using the Anti-Protozoan Drug Α-Difluoromethylornithine (DFMO) in Combination with GC7 and Aurothioglucose Blood. 132: 2725-2725. DOI: 10.1182/Blood-2018-99-117229 |
0.357 |
|
| 2017 |
Gore L, Triche TJ, Farrar JE, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Martin L, ... Narendran A, et al. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Clinical Epigenetics. 9: 108. PMID 29034009 DOI: 10.1186/S13148-017-0411-X |
0.321 |
|
| 2017 |
Meier-Stephenson V, Riemer J, Narendran A. The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia. Oncotargets and Therapy. 10: 2581-2593. PMID 28553123 DOI: 10.2147/Ott.S136484 |
0.394 |
|
| 2017 |
Cooper TM, Sison EA, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). Pediatric Blood & Cancer. PMID 28409853 DOI: 10.1002/Pbc.26414 |
0.359 |
|
| 2017 |
Bourhill T, Narendran A, Johnston RN. Enzastaurin: A lesson in drug development. Critical Reviews in Oncology/Hematology. 112: 72-79. PMID 28325267 DOI: 10.1016/J.Critrevonc.2017.02.003 |
0.383 |
|
| 2017 |
Kariminia A, Ivison SM, Leung VM, Sung S, Couto N, Rozmus J, Rolf N, Narendran A, Dunn SE, Reid GS, Schultz KR. Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia. Oncology Letters. 13: 497-505. PMID 28123588 DOI: 10.3892/Ol.2016.5437 |
0.365 |
|
| 2016 |
Singh A, Meier-Stephenson V, Jayanthan A, Narendran A. In Vitro Sensitivity Profiling Of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library To Identify Agents For Future Therapeutic Studies. Current Cancer Drug Targets. PMID 27875952 DOI: 10.2174/1568009617666161122145219 |
0.769 |
|
| 2016 |
Sooriyaarachchi M, George GN, Pickering IJ, Narendran A, Gailer J. Tuning the metabolism of the anticancer drug cisplatin with chemoprotective agents to improve its safety and efficacy. Metallomics : Integrated Biometal Science. PMID 27722429 DOI: 10.1039/C6Mt00183A |
0.355 |
|
| 2016 |
Bertram K, Irvine T, Tailor P, Narendran A, Krawetz R. Identification of p21 inhibitors to enhance chondrogenesis in osteoarthritic synovial mesenchymal progenitor cells Osteoarthritis and Cartilage. 24: S461. DOI: 10.1016/J.Joca.2016.01.841 |
0.359 |
|
| 2015 |
Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, ... ... Narendran A, et al. Tumour exosome integrins determine organotropic metastasis. Nature. PMID 26524530 DOI: 10.1038/Nature15756 |
0.324 |
|
| 2015 |
Singh A, Ruan Y, Tippett T, Narendran A. Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells. Journal of Experimental & Clinical Cancer Research : Cr. 34: 104. PMID 26384788 DOI: 10.1186/S13046-015-0222-X |
0.467 |
|
| 2015 |
McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neuro-Oncology. 17: 1086-94. PMID 25605818 DOI: 10.1093/Neuonc/Nou359 |
0.437 |
|
| 2015 |
Ruan Y, Kovalchuk A, Jayanthan A, Lun X, Nagashima Y, Kovalchuk O, Wright JR, Pinto A, Kirton A, Anderson R, Narendran A. Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy. Neuro-Oncology. 17: 822-31. PMID 25395461 DOI: 10.1093/Neuonc/Nou310 |
0.734 |
|
| 2014 |
Morris TT, Ruan Y, Lewis VA, Narendran A, Gailer J. Fortification of blood plasma from cancer patients with human serum albumin decreases the concentration of cisplatin-derived toxic hydrolysis products in vitro. Metallomics : Integrated Biometal Science. 6: 2034-41. PMID 25255207 DOI: 10.1039/C4Mt00220B |
0.308 |
|
| 2014 |
Jayanthan A, Ruan Y, Truong TH, Narendran A. Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents. Plos One. 9: e102741. PMID 25048812 DOI: 10.1371/Journal.Pone.0102741 |
0.744 |
|
| 2014 |
Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. International Journal of Molecular Sciences. 15: 2494-516. PMID 24531137 DOI: 10.3390/Ijms15022494 |
0.43 |
|
| 2014 |
Spence T, Perotti C, Sin-Chan P, Picard D, Wu W, Singh A, Anderson C, Blough MD, Cairncross JG, Lafay-Cousin L, Strother D, Hawkins C, Narendran A, Huang A, Chan JA. A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes. Neuro-Oncology. 16: 62-71. PMID 24311633 DOI: 10.1093/Neuonc/Not162 |
0.375 |
|
| 2014 |
Perinpanayagam M, Kovalchuk A, Ruan Y, Kang S, Jayanthan A, Kovalchuk O, Boklan J, Narendran A. Establishment and Drug Sensitivity, Gene Expression and Epigenetic Characterization of a Pediatric Leukemia Cell Line (POETIC1) with Primary Resistance to Decitabine Blood. 124: 983-983. DOI: 10.1182/Blood.V124.21.983.983 |
0.748 |
|
| 2014 |
Kieran MW, Yao X, Macy M, Leary S, Cohen K, MacDonald T, Allen J, Boklan J, Smith A, Nazemi K, Gore L, Trippett T, DiRenzo J, Narendran A, Perentesis J, et al. FINAL RESULTS OF A PROSPECTIVE MULTI-INSTITUTIONAL PHASE II STUDY OF EVEROLIMUS (RAD001), AN MTOR INHIBITOR, IN PEDIATRIC PATIENTS WITH RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA. A POETIC CONSORTIUM TRIAL Neuro-Oncology. 16: iii27-iii27. DOI: 10.1093/Neuonc/Nou208.15 |
0.389 |
|
| 2014 |
Ruan Y, Jayanthan A, Cooper T, Narendran A. 588 Neddylation as a therapeutic target in refractory pediatric malignancies: Evaluation of the activating enzyme inhibitor MLN4924 European Journal of Cancer. 50: 189-190. DOI: 10.1016/S0959-8049(14)70714-2 |
0.683 |
|
| 2014 |
Reimer J, Kovulchuk A, Ruan Y, Shah R, Jayanthan A, Perinpanayagam M, Truong T, Auer-Grzesiak I, Luider J, Kovulchuk O, Trippett T, Narendran A. 411 Druggability of p16 deleted pediatric leukemia: The novel cell line POETIC3 identifies potential agents and drug combinations for mechanism based targeted therapeutics European Journal of Cancer. 50: 131. DOI: 10.1016/S0959-8049(14)70537-4 |
0.716 |
|
| 2013 |
Triscott J, Lee C, Foster C, Manoranjan B, Pambid MR, Berns R, Fotovati A, Venugopal C, O'Halloran K, Narendran A, Hawkins C, Ramaswamy V, Bouffet E, Taylor MD, Singhal A, et al. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. Cancer Research. 73: 6734-44. PMID 24019381 DOI: 10.1158/0008-5472.Can-12-4331 |
0.474 |
|
| 2013 |
Lun X, Ruan Y, Jayanthan A, Liu DJ, Singh A, Trippett T, Bell J, Forsyth P, Johnston RN, Narendran A. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Molecular Oncology. 7: 944-54. PMID 23816608 DOI: 10.1016/J.Molonc.2013.05.004 |
0.709 |
|
| 2013 |
August KJ, Narendran A, Neville KA. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions. Drugs. 73: 439-61. PMID 23568274 DOI: 10.1007/S40265-013-0026-2 |
0.412 |
|
| 2013 |
Singh A, Lun X, Jayanthan A, Obaid H, Ruan Y, Strother D, Chi SN, Smith A, Forsyth P, Narendran A. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. Molecular Oncology. 7: 497-512. PMID 23375777 DOI: 10.1016/J.Molonc.2013.01.001 |
0.768 |
|
| 2013 |
Jayanthan A, Cooper TM, Hoeksema KA, Lotfi S, Woldum E, Lewis VA, Narendran A. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells. Leukemia & Lymphoma. 54: 1505-16. PMID 23176524 DOI: 10.3109/10428194.2012.752079 |
0.77 |
|
| 2013 |
Macy M, Kieran MW, Chi SN, Cohen KJ, MacDonald T, Smith AA, Etzl MM, Narendran A, Gore L, DiRenzo J, Trippett TM, Foreman NK, Dunkel IJ. A phase II trial of radiation and cetuximab followed by irinotecan/cetuximab for children with newly diagnosed diffuse pontine tumors and high-grade astrocytomas. Journal of Clinical Oncology. 31: 10030-10030. DOI: 10.1200/Jco.2013.31.15_Suppl.10030 |
0.308 |
|
| 2013 |
Cooper TM, Baker SD, Direnzo J, Trippett TM, Gore L, Narendran A, August KJ, Absalon MJ, Boklan J, Pollard J, Magoon D, R. Sison EA, Brown P. Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS Blood. 122: 2680-2680. DOI: 10.1182/Blood.V122.21.2680.2680 |
0.377 |
|
| 2013 |
Jayanthan A, Ruan Y, Hagerty M, Shah R, Truong T, Lewis VA, Boklan J, Trippett T, Gore L, Narendran A. In Vitro Growth Inhibition, Target Modulation and Drug Synergy In Pediatric Leukemia By The Novel Proteasome Inhibitor Carfilzomib Blood. 122: 2673-2673. DOI: 10.1182/Blood.V122.21.2673.2673 |
0.785 |
|
| 2013 |
Ruan Y, Liu D, Jayanthan A, Truong T, Boklan J, Narendran A. Abstract C205: Cytotoxicity and target modulation in pediatric solid tumors by the proteasome inhibitor carfilzomib. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C205 |
0.771 |
|
| 2013 |
Hagerty M, Jayanthan A, Ruan Y, Trippett T, Narendran A. Abstract C175: Effective targeting of PI3K/mTOR pathways with GDC-0980 in FLT-3 mutant pediatric leukemia. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C175 |
0.759 |
|
| 2013 |
Trippett TM, Smith A, Neville K, Chi S, Narendran A, Arceci R, Direnzo J, Gore L. Abstract B81: Phase I/II trial of vorinostat in combination with etoposide in pediatric patients with relapsed/refractory solid tumors. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B81 |
0.331 |
|
| 2012 |
Hasselblatt M, Kordes U, Wolff J, Jeibmann A, Frühwald M, Paulus W, Isken S, Siebert R, Schneppenheim R, Benesch M, Fleischhack G, Gruhn B, Schlegel P, Witt O, Holter W, ... ... Narendran A, et al. Atypical Teratoid Rhabdoid Tumor (Atrt) Neuro-Oncology. 14. PMID 22745951 DOI: 10.1093/Neuonc/Nos091 |
0.673 |
|
| 2012 |
Steele M, Narendran A. Mechanisms of defective erythropoiesis and anemia in pediatric acute lymphoblastic leukemia (ALL). Annals of Hematology. 91: 1513-8. PMID 22543829 DOI: 10.1007/S00277-012-1475-5 |
0.356 |
|
| 2012 |
de Oliveira JC, Brassesco MS, Scrideli CA, Tone LG, Narendran A. MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL). Pediatric Blood & Cancer. 59: 599-604. PMID 22492670 DOI: 10.1002/Pbc.24167 |
0.312 |
|
| 2012 |
Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, et al. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Stem Cells (Dayton, Ohio). 30: 1064-75. PMID 22415968 DOI: 10.1002/Stem.1081 |
0.747 |
|
| 2012 |
Banderali U, Jayanthan A, Hoeksema KA, Narendran A, Giles WR. Ion channels in pediatric CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) cells: potential targets for novel therapeutic agents. Journal of Neuro-Oncology. 107: 111-9. PMID 21971736 DOI: 10.1007/S11060-011-0735-X |
0.751 |
|
| 2012 |
Mummery A, Narendran A, Lee KY. Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia. Current Cancer Drug Targets. 11: 882-93. PMID 21762078 DOI: 10.2174/156800911796798922 |
0.408 |
|
| 2012 |
Jayanthan A, Cooper T, Dunn SE, Lewis VA, Narendran A. Cooperative Lethality of Polo-Like Kinases (PLK) and Aurora Kinases (AK) in Refractory Pediatric Leukemia Blood. 120: 3573-3573. DOI: 10.1182/Blood.V120.21.3573.3573 |
0.766 |
|
| 2012 |
Clarkson MF, Narendran A, Johnston RN. Preclinical Evaluation of Oncolytic Reovirus in Targeted Therapeutics for High-Risk Pediatric Leukemia Blood. 120: 3571-3571. DOI: 10.1182/Blood.V120.21.3571.3571 |
0.526 |
|
| 2012 |
Gore L, Macy ME, Mechinaud F, Narendran A, Alvaro F, Arndt CA, Barnette P, Boklan J, Cooper T, Martin L, Tcheng W, Tarassoff P, Jones MM, Meshinchi S, Arceci RJ. Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML) Blood. 120: 1517-1517. DOI: 10.1182/Blood.V120.21.1517.1517 |
0.349 |
|
| 2012 |
Kariminia A, Ivison SM, Leung V, Dunn SE, Narendran A, Schultz KR. YB-1 Is Activated by IL-7 and Is Overexpressed in Pediatric Pre-B Acute Lymphoblastic Leukemia Blood. 120: 1468-1468. DOI: 10.1182/Blood.V120.21.1468.1468 |
0.354 |
|
| 2012 |
McKenzie B, Zemp FJ, Lun X, Narendran A, McFadden G, Kurz E, Forsyth P. Abstract LB-140: Targeting brain tumour initiating cells using a dual-pronged approach of oncolytic virotherapy and chemotherapeutics Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-140 |
0.468 |
|
| 2012 |
Leonard A, Wolff J, Sengupta R, Marassa J, Piwnica-Worms D, Rubin J, Pollack I, Jakacki R, Butterfield L, Okada H, Fangusaro J, Warren KE, Mullins C, Jurgen P, Julia S, ... ... Narendran A, et al. HIGH GRADE GLIOMAS Neuro-Oncology. 14: i56-i68. DOI: 10.1093/Neuonc/Nos102 |
0.642 |
|
| 2011 |
Jayanthan A, Bernoux D, Bose P, Riabowol K, Narendran A. Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. Cancer Cell International. 11: 44. PMID 22206574 DOI: 10.1186/1475-2867-11-44 |
0.757 |
|
| 2011 |
Banderali U, Belke D, Singh A, Jayanthan A, Giles WR, Narendran A. Curcumin blocks Kv11.1 (erg) potassium current and slows proliferation in the infant acute monocytic leukemia cell line THP-1. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 28: 1169-80. PMID 22179005 DOI: 10.1159/000335850 |
0.743 |
|
| 2011 |
Maddigan A, Truitt L, Arsenault R, Freywald T, Allonby O, Dean J, Narendran A, Xiang J, Weng A, Napper S, Freywald A. EphB receptors trigger Akt activation and suppress Fas receptor-induced apoptosis in malignant T lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 187: 5983-94. PMID 22039307 DOI: 10.4049/Jimmunol.1003482 |
0.396 |
|
| 2011 |
Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A. Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. Oncotargets and Therapy. 4: 149-68. PMID 21949608 DOI: 10.2147/Ott.S21553 |
0.748 |
|
| 2011 |
Singh A, Jayanthan A, Farran A, Elwi AN, Kim SW, Farran P, Narendran A. Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition. Leukemia Research. 35: 1649-57. PMID 21798596 DOI: 10.1016/J.Leukres.2011.06.035 |
0.749 |
|
| 2011 |
Blackmore C, Jayanthan A, Ujack E, Magliocco T, Narendran A. Analysis of multiple growth regulatory proteins using dissociable staining antibody arrays on solid tumor biopsy specimens Fetal and Pediatric Pathology. 30: 177-188. PMID 21355677 DOI: 10.3109/15513815.2010.547558 |
0.708 |
|
| 2011 |
Jayanthan A, Incoronato A, Singh A, Blackmore C, Bernoux D, Lewis V, Stam R, Whitlock JA, Narendran A. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement. Pediatric Blood & Cancer. 56: 353-60. PMID 21225911 DOI: 10.1002/Pbc.22760 |
0.739 |
|
| 2011 |
Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford, England). 50: 417-9. PMID 20693540 DOI: 10.1093/rheumatology/keq218 |
0.648 |
|
| 2011 |
Koro K, Parkin S, Pohorelic B, Yang AD, Narendran A, Egan C, Magliocco A. Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration. Breast Cancer Research and Treatment. 126: 73-83. PMID 20401631 DOI: 10.1007/S10549-010-0889-9 |
0.34 |
|
| 2011 |
Štrbák V, Eduardsen K, Larsen SL, Novak I, Lambert IH, Hoffmann EK, Pedersen SF, Li A, Banerjee J, Leung CT, Peterson-Yantorno K, Stamer WD, Civan MM, Ellis DZ, Schedlbauer A, ... ... Narendran A, et al. The Na (+)/H+ Exchanger Nhe-1, A Crucial Cellular Integrator Controlled By Its Membrane Environment Cellular Physiology and Biochemistry. 28: 1295-1330. DOI: 10.1159/000335868 |
0.622 |
|
| 2011 |
Štrbák V, Eduardsen K, Larsen SL, Novak I, Lambert IH, Hoffmann EK, Pedersen SF, Li A, Banerjee J, Leung CT, Peterson-Yantorno K, Stamer WD, Civan MM, Ellis DZ, Schedlbauer A, ... ... Narendran A, et al. Contents Vol. 28, 2011 Cellular Physiology and Biochemistry. 28. DOI: 10.1159/000335863 |
0.612 |
|
| 2010 |
Blackmore C, Coppes MJ, Narendran A. Candidate genes and potential targets for therapeutics in Wilms' tumour Clinical and Translational Oncology. 12: 597-605. PMID 20851800 DOI: 10.1007/S12094-010-0564-Y |
0.377 |
|
| 2010 |
Jayanthan A, Miettunen PM, Incoronato A, Ortiz-Neira CL, Lewis VA, Anderson R, Frohlich DE, Narendran A. Childhood acute lymphoblastic leukemia (ALL) presenting with severe osteolysis: a model to study leukemia-bone interactions and potential targeted therapeutics. Pediatric Hematology and Oncology. 27: 212-27. PMID 20367265 DOI: 10.3109/08880011003663382 |
0.718 |
|
| 2010 |
Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, ... ... Narendran A, et al. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatric Blood & Cancer. 54: 872-8. PMID 20127846 DOI: 10.1002/Pbc.22414 |
0.381 |
|
| 2010 |
Jayanthan A, Singh A, Lewis VA, Narendran A. Preclinical Studies of Cytotoxicity, Drug Synergy and Biological Correlates of Clofarabine Against Infant Leukemia Cells Blood. 116: 4342-4342. DOI: 10.1182/Blood.V116.21.4342.4342 |
0.75 |
|
| 2009 |
Jayanthan A, Howard SC, Trippett T, Horton T, Whitlock JA, Daisley L, Lewis V, Narendran A. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leukemia & Lymphoma. 50: 1174-82. PMID 19557638 DOI: 10.1080/10428190902943069 |
0.748 |
|
| 2009 |
Lotfi S, Jayanthan A, Lewis VA, Guilcher G, Squires MS, Cooper T, Narendran A. AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells. Blood. 114: 3078-3078. DOI: 10.1182/Blood.V114.22.3078.3078 |
0.766 |
|
| 2009 |
Miettunen P, Jayanthan A, Incoronato A, Narendran A. An experimental approach to understand tumor initiated processes that result in bone osteolysis in pediatric acute lymphoblastic leukemia patients Bone. 45: S94. DOI: 10.1016/J.Bone.2009.04.143 |
0.686 |
|
| 2008 |
Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment. Journal of Experimental Therapeutics & Oncology. 7: 183-93. PMID 19066127 |
0.663 |
|
| 2008 |
Narendran A, Coppes L, Jayanthan A, Coppes M, Teja B, Bernoux D, George D, Strother D. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics. Journal of Neuro-Oncology. 90: 171-80. PMID 18651103 DOI: 10.1007/S11060-008-9653-Y |
0.75 |
|
| 2008 |
Jiang G, Freywald T, Webster J, Kozan D, Geyer R, DeCoteau J, Narendran A, Freywald A. In human leukemia cells ephrin-B-induced invasive activity is supported by Lck and is associated with reassembling of lipid raft signaling complexes. Molecular Cancer Research : McR. 6: 291-305. PMID 18314490 DOI: 10.1158/1541-7786.Mcr-07-0047 |
0.344 |
|
| 2008 |
Miettunen P, Jayanthan A, Narendran A. 7.3 Successful use of anakinra, a soluble IL-1 receptor antagonist, in pediatric rheumatic diseases associated macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis Pediatric Rheumatology. 6. DOI: 10.1186/1546-0096-6-S1-S13 |
0.645 |
|
| 2007 |
Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1783-8. PMID 17363533 DOI: 10.1158/1078-0432.Ccr-06-1892 |
0.346 |
|
| 2006 |
Connor AM, Berger S, Narendran A, Keystone EC. Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts. Arthritis Research & Therapy. 8: R94. PMID 16774691 DOI: 10.1186/Ar1968 |
0.327 |
|
| 2006 |
Barlow JW, Wiley JC, Mous M, Narendran A, Gee MF, Goldberg M, Sexsmith E, Malkin D. Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatric Blood & Cancer. 47: 773-84. PMID 16283617 DOI: 10.1002/Pbc.20650 |
0.327 |
|
| 2006 |
Ganjavi H, Gee M, Narendran A, Parkinson N, Krishnamoorthy M, Freedman MH, Malkin D. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Therapy. 13: 415-9. PMID 16211088 DOI: 10.1038/Sj.Cgt.7700909 |
0.402 |
|
| 2005 |
Hawkins LM, Narendran A. The geldanamycin derivative 17-AAG decreases VEGF secretion and leukemia growth support by trisomy 8 myelodysplastic syndrome bone marrow stromal cells. Pediatric Hematology and Oncology. 22: 115-25. PMID 15804996 DOI: 10.1080/08880010590896477 |
0.407 |
|
| 2005 |
Hawkins LM, Jayanthan AA, Narendran A. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatric Research. 57: 430-7. PMID 15659698 DOI: 10.1203/01.Pdr.0000153871.45184.19 |
0.754 |
|
| 2005 |
Ganjavi H, Gee M, Narendran A, Freedman MH, Malkin D. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Therapy. 12: 397-406. PMID 15618970 DOI: 10.1038/Sj.Cgt.7700798 |
0.428 |
|
| 2005 |
Jayanthan A, Fowler J, Coppes L, Trippett T, Anderson R, Narendran A. Additive Interaction between Oxaliplatin and DMAG in Pediatric Acute Lymphoblastic Leukemia (ALL) Cells. Evidence for Interference with Multiple Signaling Pathways. Blood. 106: 4590-4590. DOI: 10.1182/blood.v106.11.4590.4590 |
0.378 |
|
| 2005 |
Ding Y, Teja B, Blackmore C, Dingwa S, Ujack E, Brown C, Narendran A. Studies on GM-CSF Induced Signaling and Cell Growth in JMML: An Experimental Model To Identify Mechanism Directed Targeted Therapeutics. Blood. 106: 2765-2765. DOI: 10.1182/Blood.V106.11.2765.2765 |
0.436 |
|
| 2004 |
Narendran A, Hawkins LM, Ganjavi H, Vanek W, Gee MF, Barlow JW, Johnson G, Malkin D, Freedman MH. Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. Pediatric Hematology and Oncology. 21: 209-21. PMID 15202160 DOI: 10.1080/08880010490276917 |
0.403 |
|
| 2004 |
Dror Y, Grunebaum E, Hitzler J, Narendran A, Ye C, Tellier R, Edwards V, Freedman MH, Roifman CM. Purine nucleoside phosphorylase deficiency associated with a dysplastic marrow morphology. Pediatric Research. 55: 472-7. PMID 14711904 DOI: 10.1203/01.Pdr.0000111286.23110.F8 |
0.362 |
|
| 2004 |
Narendran A, Tijan B, Coppes L, Rhemtulah F, Anderson R. In Vitro Growth Regulation and the Identification of Potential Signaling Pathways in T (4; 11), Pediatric Pre-B Acute Lymphoblastic Leukemia (ALL). Blood. 104: 1896-1896. DOI: 10.1182/Blood.V104.11.1896.1896 |
0.399 |
|
| 2003 |
Narendran A, Ganjavi H, Morson N, Connor A, Barlow JW, Keystone E, Malkin D, Freedman MH. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Experimental Hematology. 31: 693-701. PMID 12901974 DOI: 10.1016/S0301-472X(03)00159-0 |
0.394 |
|
| 1993 |
Narendran A, Ramsden D, Cumano A, Tanaka T, Wu GE, Paige CJ. B cell developmental defects in X-linked immunodeficiency. International Immunology. 5: 139-44. PMID 7680896 DOI: 10.1093/Intimm/5.2.139 |
0.349 |
|
| 1992 |
Cumano A, Narendran A, Paige CJ. Factors produced by stromal cells involved in B-cell development. Advances in Experimental Medicine and Biology. 303: 191-7. PMID 1805565 DOI: 10.1007/978-1-4684-6000-1_20 |
0.343 |
|
| Show low-probability matches. |